Editas Medicine Inc/ US28106W1036 /
2024-03-28 9:00:00 PM | Chg. -0.0200 | Volume | Bid11:06:00 PM | Ask11:06:00 PM | High | Low |
---|---|---|---|---|---|---|
7.4200USD | -0.27% | 1.56 mill. Turnover: 9.67 mill. |
7.4500Bid Size: 100 | 7.4800Ask Size: 600 | 7.5200 | 7.3650 |
GlobeNewswire
03-20
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
GlobeNewswire
02-28
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
GlobeNewswire
02-21
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Inv...
GlobeNewswire
01-08
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan H...
GlobeNewswire
2023-12-13
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
GlobeNewswire
2023-12-11
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at t...
GlobeNewswire
2023-11-07
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
GlobeNewswire
2023-11-02
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 202...
GlobeNewswire
2023-10-27
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
GlobeNewswire
2023-10-16
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 f...
GlobeNewswire
2023-09-25
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
GlobeNewswire
2023-09-25
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Co...
GlobeNewswire
2023-08-28
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
GlobeNewswire
2023-08-28
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
GlobeNewswire
2022-03-09
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
GlobeNewswire
2022-02-28
Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent ...
GlobeNewswire
2022-02-24
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
GlobeNewswire
2022-02-16
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Cor...
GlobeNewswire
2022-01-10
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
GlobeNewswire
2022-01-04
Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference